Anshu Hemrajani
Medical Oncology · Glenview, ILNPI 1548653231
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $820 of the $1,326 with a category attached, or 61.9%. It is spread thinly across 10 manufacturers, the largest accounting for just 21.6%. Reporting peaked in 2022 at $532 and has fallen 95.7% since, to $23 in 2025. That places this record below the midpoint for medical oncology clinicians in IL, where the typical reported total is $1,059.
Across 15 payments — averaging $88.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$286
- Sanofi-aventis U.S. LLC$198
- Incyte Corporation$194
- Sanofi$187
- Exelixis Inc.$157
- ADC Therapeutics America, Inc.$123
- plus $182 from 4 others
Across 1 payment — averaging $10,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$10K
What the payments were for
- Food & beverage$82062%
- Education$50638%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 3 | $286 |
| Sanofi-aventis U.S. LLC | 2 | $198 |
| Incyte Corporation | 2 | $194 |
| Sanofi | 2 | $187 |
| Exelixis Inc. | 1 | $157 |
| ADC Therapeutics America, Inc. | 1 | $123 |
| Epizyme, Inc. | 1 | $78 |
| Regeneron Healthcare Solutions, Inc. | 1 | $68 |
| Boehringer Ingelheim | 1 | $23 |
| Karyopharm Therapeutics Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,326 in reported general payments places this provider in the 50th percentile of 144 medical oncology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KisqaliRibociclib Succinate | 22 | $326,314 |
| Anastrozole | 279 | $4,657 |
| Exemestane | 20 | $1,781 |
| Letrozole | 78 | $1,215 |
| Nystatin | 14 | $355 |
| Tamoxifen Citrate | 14 | $272 |
| Famotidine | 15 | $155 |
| Dexamethasone | 11 | $154 |
| Prochlorperazine Maleate | 16 | $109 |
| Ondansetron Hcl | 18 | $80 |
| Lorazepam | 13 | $62 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Glenview
- Nicklas PfanzelterGlenview$199K
- Ruta RaoChicago$328K
- Sunandana ChandraChicago$292K
- William GradisharChicago$289K
- Timothy KuzelOrland Park$265K
- Devalingam MahalingamChicago$252K
- Mary FidlerChicago$241K
- James WallaceChicago$229K
- Andrzej JakubowiakChicago$215K
- Jyoti PatelChicago$175K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.